Findings

What do systematic reviews say?

4 questions · 4 findings · 3 reviews · Hypertension

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Combination therapy vs monotherapy

Serious adverse events · people with primary hypertension

It is very uncertain whether combination therapy changes serious adverse events compared with monotherapy (very low certainty).

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
RR 0.77 [0.31, 1.92]
3 studies · 568 participants
Very low

Antihypertensive drug therapy vs placebo or no treatment

Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy

It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Pharmacotherapy for hypertension‐induced left ventricular hypertrophy 2021 · Cochrane Headline outcomes only
RR 1.02 [0.89, 1.16]
3 studies · 930 participants
Very low

Combination with potassium‐sparing diuretics vs monotherapy

Serious adverse events · people with primary hypertension

It is very uncertain whether combination with potassium‐sparing diuretics changes serious adverse events compared with monotherapy (very low certainty).

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
RR 0.72 [0.1, 5.04]
1 study · 200 participants
Very low

Evening vs morning dosing regimen

Serious adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater

It is very uncertain whether evening changes serious adverse events compared with morning dosing regimen (very low certainty).

1 finding from 1 review

Evening versus morning dosing regimen drug therapy for hypertension 2024 · Cochrane Headline outcomes only
RR 1.17 [0.53, 2.57]
2 studies · 833 participants
Very low